Antibacterial Agents TRIZ Cases

Anti-CD47 antibodies block the CD47-SIRPα interaction, enabling phagocytic antigen-presenting cells to engulf tumor cells and prime cytotoxic T cell responses.

Surface-modified particles use a surfactant coating to enhance cellular uptake of therapeutic agents.

Scyreprocin inhibits cancer proliferation via selective receptor binding, resolving cytotoxicity trade-offs in chemotherapy.

Compounds disrupt sigma factor interactions to inhibit bacterial transcription, addressing inadequate treatments for resistant infections.

Oral Enterococcus bacterium combats multidrug-resistant Pseudomonas aeruginosa strains by enhancing intestinal immunity to improve survival rates.

IVIAT identifies recombinant antigens Mdh, D15, and AfuA to distinguish naturally infected animals from vaccinated ones.

Fc-beta2GPI constructs bind phosphatidylserine on tumor endothelial cells to deliver therapeutic agents.

Unsaturated long chain alcohols and aldehydes disrupt biofilm matrices, enabling antimicrobials to penetrate surfaces where mechanical removal fails.

Next Generation Bioengineered Probiotics display Listeria adhesion protein to prevent L. monocytogenes infection by blocking epithelial barrier crossing.

An anti-IL-1RA monoclonal antibody neutralizes the antagonist to restore IL-1 signaling in chronic Lyme disease treatment.

Niclosamide binds GSK3 to disrupt the Axin-GSK3 complex, reducing Wnt activity and treating familial adenomatosis polyposis.

Segmented comb-type polymers attach targeting ligands to pendant chains, resolving the trade-off between drug solubilization and biocompatibility.

Bicyclic aryl monobactam compounds overcome limited efficacy against resistant strains by enhancing antibiotic strength via parameter changes.

Spray-dried Lactobacillus cells form stable co-aggregates with Helicobacter pylori, preventing gastric mucosa penetration and reducing chronic inflammation.

Ramipril and folic acid enhance nitric oxide bioavailability to protect retinal cells.

Segmenting transrepression from transactivation reduces side effects while maintaining anti-inflammatory efficacy.

Pantoea lipopolysaccharide adjuvant induces systemic and mucosal immunity without severe side effects.

Combines beta-lactamase inhibitor compound 1 with sulbactam to restore antibiotic efficacy against resistant pathogens.

Substituted hydroxamic acid derivatives target the conserved LpxC active site, overcoming multidrug resistance in Gram-negative pathogens.

Composite dermal fillers incorporate cationic steroidal antimicrobials to prevent microbial contamination and biofilm formation, accelerating tissue repair.

Esc-COP-7 phage kills pathogenic E. coli while preserving commensal flora, avoiding antibiotic resistance and environmental pollution.

Nepenthesin protease degrades gluten and bacterial endospore coats, bypassing antibiotic resistance.

Antivirulence compounds potentiate antibiotics to suppress bacterial growth and treat resistant infections.

A composite preservative system combining levulinic acid with benzoic and sorbic acids to inhibit microbial growth.

A nitric oxide releasing tympanostomy tube sequesters and releases antimicrobial gas through a permeable silicone structure.

Intravenous BCG with adjuvants induces robust antigen-responsive CD4 and CD8 T cells to protect against Mycobacterium tuberculosis.

Antibodies bind human protein tyrosine phosphatase beta to regulate angiogenic cell signaling and enhance capillary morphogenesis.

Substituted 7-methyl quinoline derivatives address drug resistance and side effects by targeting multi-drug resistant strains with novel molecular scaffolds.

Chimeric OspA molecules combine proximal and distal portions from different serotypes to create stable antigens.

Steroid alkaloids inhibit electron transport-deficient microbes and potentiate aminoglycoside activity against resistant pathogens.

A truncated TLR3 variant lacking residues 289 to 352 suppresses receptor activity.

Local quality design on the triazine ring enables selective inhibition of CDK9, resolving low efficacy against this enzyme target.

Tricyclic sulfonamide compounds inhibit MetAP2 to increase fat oxidation and reduce food consumption, addressing obesity without harmful side effects.

Chimeric invasin and outer membrane proteins expose specific antigenic domains to trigger robust cellular immune responses without live bacteria risks.

Nano-coated electrodes and pulsed fields stabilize electrolytic water, extending shelf life while removing heavy metals.

Mesenchymal stem cell-derived exosomes deliver therapeutic markers to treat lung and cardiovascular conditions.

Chex1-Arg20 peptide sequence incorporates non-natural amino acids to resist proteolytic degradation, reducing immunogenicity while preserving in vivo efficacy.

Extended intravenous peptide infusion reduces myalgia and fever by applying periodic dosing to maintain sustained therapeutic effects.

Beta glycolipids modulate the Th1/Th2 cell balance to alleviate inflammatory disorders.

Dynamic reactant addition in enzymatic cefaclor synthesis maintains optimal molar ratios to minimize by-product formation while achieving high conversion rates.

Kukoamine B salts neutralize pathogen-associated molecular patterns to inhibit inflammatory mediator release.

Novel endolysin polypeptides degrade Gardnerella vaginalis biofilms to prevent recurrence while preserving healthy vaginal flora balance.

Neutrophil gelatinase-associated lipocalin peptide treats acne and psoriasis without teratogenic risks of isotretinoin.

Acidic intimate cleansing composition uses lactic acid and anionic surfactant system to resolve irritation versus cleaning effectiveness trade-off.